Business
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
TOKYO, May 11, 2026--Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncology revenue by 2030 and be a global top five oncology company by 2035 as part of its larger 2035 Vision to be recognized as a "trusted healthcare innovator transforming the lives of people through science and technology."
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/078b3bf5fb07e9d2b818299d9b5d2051"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gjaeBomUaC4gxDVRZ.GqYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0OA--/https://media.zenfs.com/en/business-wire.com/078b3bf5fb07e9d2b818299d9b5d2051","width":480,"height":474},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/DIejEjStzoInNiQYE.scfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTYzMg--/https://media.zenfs.com/en/business-wire.com/078b3bf5fb07e9d2b818299d9b5d2051","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"2.3 trillion yen in oncology revenue to be delivered by 2030 through the launch of 20 new indications across five medicines","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Identifying breakthrough generating technologies and strengthening of standalone clinical development and commercialization capabilities represent the foundation for continued growth beyond 2030","length":194,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Daiichi Sankyo to be a global top five oncology company by 2035","length":63,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":380,"olType":false},{"type":"text","content":"TOKYO, May 11, 2026--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncology revenue by 2030 and be a global top five oncology company by 2035 as part of its larger 2035 Vision to be recognized as a "trusted healthcare innovator transforming the lives of people through science and technology."","length":444,"tagName":"p"},{"type":"text","content":"The new Five-Year Business Plan reinforces the enduring purpose of Daiichi Sankyo to contribute to the enrichment of quality of life around the world, and central to this growth strategy is an intensified focus on its mission to create new medicines for patients by leveraging the company’s expertise in science and technology.","length":327,"tagName":"p"},{"type":"text","content":""Our new five-year business plan represents a defining...